Grifols SA (GIKLY) income statement

GIKLYOTCPharmaceutical PreparationsAlso trades as GIFLF, GIFOF, GRFS

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 17, 2026Score 9/30

$5.55+0.00 (0.00%)

Close on Oct 19, 2026Market cap $1.91BP/E 4.2Yield –

Grifols SA income statement

AnnualQuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	7,524	7,212	6,592	6,064	4,933	5,340	5,099	4,487	4,318	4,050	3,935
Cost of Revenue	4,665	4,418	4,109	3,850	2,971	3,085	2,757	2,437	2,166	2,138	2,004
Gross Profit	2,859	2,794	2,483	2,214	1,963	2,255	2,341	2,050	2,152	1,912	1,931
Research & Development	426	384	395	361	355	294	276	241	288	198	224
Selling, General & Admin	1,183	1,255	1,373	1,196	1,062	986	943	815	860	775	736
Selling & Marketing	–	–	–	91	71	55	59	45	50	51	48
Advertising Expenses	81	85	80	92	71	–	–	–	–	–	–
Operating Expenses	1,609	1,639	1,768	1,557	1,416	1,280	1,219	1,055	1,149	973	961
Operating Income	1,243	1,192	782	782	595	996	1,131	994	1,003	939	970
Interest Expense	625	714	597	478	268	250	343	293	263	245	240
Interest & Investment Income	34	44	62	34	12	8.02	114	14	9.68	9.93	5.84
Income from Equity Investments	–	–	-0.92	-1.48	33	60	-40	-11	-20	6.93	-8.28
Pretax Income	615	444	206	338	350	879	817	726	696	713	690
Income Tax Expense	115	231	43	90	85	170	168	131	34	168	159
Income from Continuing Operations	–	–	181	271	265	709	649	594	661	545	531
Net Income incl. Noncontrolling Interests	500	213	163	248	265	709	649	594	661	545	531
Minority Interest in Earnings	98	56	121	63	77	90	23	-2.24	-1.39	-0.91	-0.70
Net Income	402	157	42	185	189	619	625	597	663	545	532
Net Income to Common	402	157	42	185	189	619	625	597	663	545	532
EPS (Basic)(per share)	0.59	0.23	0.06	0.27	0.28	0.90	0.91	0.87	0.97	0.80	0.78
EPS (Diluted)(per share)	0.59	0.23	0.06	0.27	0.28	0.90	0.91	0.87	0.97	0.80	0.78
Shares Outstanding (Basic, Weighted)(shares)	681	680	680	680	682	686	685	685	684	683	684
Shares Outstanding (Diluted, Weighted)(shares)	682	680	677	679	681	685	685	685	684	684	684
EBITDA	1,693	1,630	1,228	1,193	955	1,318	1,434	1,223	1,219	1,141	1,160

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 38.0%
Operating margin: 16.5%
Net margin: 5.3%
Return on equity, FY2025: 7.2%

Financial strength

Current ratio: 2.51
Debt to equity: 0.41
Debt to assets: 11.0%
Cash to current liabilities: 40.9%

Valuation

P/E ratio: 4.2
Price to sales: 0.23
Price to book: 0.32
Dividend yield: –

See a number that looks wrong?